Eli Lilly Says Trump's Drug Pricing Policy Complicates European Weight-Loss Drug Launch

According to Reuters on Tuesday, June 23, Eli Lilly stated that the Trump administration's Most-Favored-Nation (MFN) drug pricing policy will complicate pricing and reimbursement negotiations for its new drug launches in Europe. The company plans to introduce an oral weight-loss medication in Europe and the UK in the second half of 2026 through early 2027, following regulatory approval in the U.S. and UAE.

Lilly will partner with telehealth platforms, e-commerce channels, and direct-to-consumer sales to expand market reach, as obesity treatment in most European countries relies primarily on patient self-payment rather than public healthcare coverage. Company executives acknowledged that the MFN policy will affect all new drug launch plans and pricing discussions, but said Lilly will continue pursuing public healthcare reimbursement where possible.